Skip to search formSkip to main contentSkip to account menu

Ciluprevir

Known as: (2R,6S,12Z,13aS,14aR,16aS)-6-(((Cyclopentyloxy)carbonyl)amino)-2-((7-methoxy-2-(2-((1-methylethyl)amino)thiazol-4-yl)quinolin-4-yl)oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxylic acid 
An orally bioavailable, peptidomimetic, macrocyclic compound with activity against hepatitis C virus (HCV). Ciluprevir binds non-covalently to the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Hepatitis C virus (HCV) currently infects over 185 million individuals around the world. Its persistence causes infected… 
2015
2015
  • J. Pawlotsky
  • Nature Reviews Gastroenterology &Hepatology
  • 2015
  • Corpus ID: 21099351
Treatment failure associated with HCV resistance to newly developed direct-acting antiviral agents is not an uncommon occurrence… 
2015
2015
Objective Direct-acting antivirals (DAAs) inhibit hepatitis C virus (HCV) infection by targeting viral proteins that play… 
2014
2014
To aid the design of next generation hepatitis C virus (HCV) drugs, the kinetics of the interactions between NS3 protease… 
Review
2007
Review
2007
This perspective is the fifth in a series discussing drugs dropped from development in 2005, of which 11 were being developed for… 
Review
2005
Review
2005
Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide and afflicts > 170 million people. The… 
Review
2004
Review
2004
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2003
2003
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the…